Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

How insurers are tackling the illiquid asset challenge
James Fermont discusses how there has been a step-change in insurers’ engagement and willingness to take on illiquid assets from DB schemes —and why
Solvency under scrutiny
The topic of solvency has garnered significant attention recently, with the results of a Europe-wide stress test shedding light on insurers’ positions
Bitcoin is it currency a store of value or pure speculation
Bitcoin has generated significant interest among investors, institutions, and governments worldwide. While some view it as a potential future currency

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.